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OBJECTIVE — Progressive nephropathy represents a substantial source of morbidity and
mortality in type 1 diabetes. Increasing albuminuria is a strong predictor of progressive renal
dysfunction and heightened cardiovascular risk. Early albuminuria probably reﬂects vascular
endothelial dysfunction, which may be mediated in part by chronic inﬂammation.
RESEARCH DESIGN AND METHODS — We measured baseline levels of four inﬂam-
matory biomarkers (high-sensitivity C-reactive protein, soluble intercellular adhesion mole-
cule-1 [sICAM-1], soluble vascular cell adhesion molecule-1, and soluble tumor necrosis
factor-receptor-1)instoredbloodsamplesfromthe1,441participantsoftheDiabetesControl
and Complication Trial (DCCT). We used mixed-effects regression models to determine the
averageannualchangeinurinaryalbuminexcretionrate(AER)bytertilesofeachbiomarker.We
also used Cox proportional hazards models to estimate the relative risk of incident sustained
microalbuminuria according to levels of each biomarker.
RESULTS — After adjustment for baseline age, sex, duration of diabetes, A1C, and random-
ized treatment assignment, we observed a signiﬁcantly higher 5.9 g   min
1   year
1 increase
in AER among those in the highest compared with the lowest tertile of baseline sICAM-1 (P 
0.04). Those in the highest tertile of sICAM-1 had an adjusted relative risk of 1.67 (95% CI
0.96–2.92) of developing incident sustained microalbuminuria (Ptrend  0.03).
CONCLUSIONS — Higher baseline sICAM-1 levels predicted an increased risk of progres-
sive nephropathy in type 1 diabetes and may represent an early risk marker that reﬂects the
important role of vascular endothelial dysfunction in this long-term complication.
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M
orbidity and mortality from kid-
ney disease and cardiovascular
disease(CVD)areimportantcom-
plications of type 1 diabetes. Develop-
ment of microalbuminuria is a signal of
relatively early nephropathy in diabetes
and is an independent risk factor for
CVD and mortality in epidemiologic
studies and secondary analyses of cardio-
vasculartrials.Withtherecognitionofthe
central role played by inﬂammatory pro-
cesses in both CVD (1) and type 1 (2) as
wellastype2diabetes(3),theassociation
between potentially modiﬁable inﬂam-
matory biomarkers and clinical outcomes
suchasnephropathyandCVDindiabetes
isofinterest.Moreover,althoughdiabetic
nephropathy has traditionally not been
considered an inﬂammatory nephritis,
more recent evidence that macrophage
accumulation is characteristic of diabetic
glomerulosclerosis has challenged this
perception (4).
A few cross-sectional studies of indi-
vidualswithtype1diabeteshavereported
associations between increased AER and
elevated levels of inﬂammatory markers
including high-sensitivity (hs) C-reactive
protein (CRP) (5), soluble (s) tumor
necrosis factor- receptor-1 (TNFR-1)
(6), intercellular adhesion molecule-1
(ICAM-1), and vascular cell adhesion
molecule-1 (VCAM-1) (7), but whether
the elevation in these markers of inﬂam-
mation precedes nephropathy progres-
sionisnotwelldescribed.Ifinﬂammation
contributes to the development of ne-
phropathy, it would represent a potential
therapeutic target for slowing the micro-
vascular and macrovascular complica-
tionsofdiabetes.Wethereforeundertook
a prospective analysis of inﬂammatory
biomarkers and change in urinary albu-
min excretion over time in 1,441 individ-
uals with type 1 diabetes participating in
the Diabetes Control and Complications
Trial (DCCT).
RESEARCH DESIGN AND
METHODS— The DCCT was a mul-
ticenter randomized trial of intensive ver-
sus conventional diabetes therapy for
type 1 diabetes in the development and
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complications. The 1,441 DCCT partici-
pants were recruited at 29 centers from
1983 through 1989. All participants were
between the ages of 13 and 39 years and
had baseline A1C levels greater than 3
SDs above the mean for individuals with-
out diabetes.
There were two strata in the DCCT,
deﬁned by the absence versus presence of
early clinical microvascular complica-
tions:1)aprimarypreventioncohortwith
no retinopathy, diabetes duration of 1–5
years, and no evidence of microalbumin-
uria at baseline (albuminuria 28 g/
min [40 mg/24 h]), and 2) a secondary
interventioncohortwithminimaltomod-
erate nonproliferative retinopathy, diabe-
tes duration between 1 and 15 years, and
140 g/min (200 mg/24 h) of albumin-
uria. After a mean follow-up of 6.5 years
(range 3–9 years), the DCCT reported
clinically and statistically highly signiﬁ-
cant reductions (range of 35–70%) in
microvascular end points in the intensive
compared with the conventional therapy
group.Follow-upintheDCCTwasnearly
complete, with subjects attending 99% of
all scheduled follow-up visits.
Laboratory studies
Fasting serum samples were obtained
fromDCCTparticipantsatbaselineandat
each annual visit. Samples were main-
tainedat70°CattheDCCTCentralBio-
chemistry Laboratory, Department of
Laboratory Medicine and Pathology, Uni-
versity of Minnesota until preparation for
thepresentstudy.Baselineserumsamples
were thawed and assayed for levels of
sICAM-1,sVCAM-1,andsTNFR-1byen-
zyme-linked immunosorbent assays
(R&D Systems, Minneapolis, MN) in the
Children’sHospitalLaboratoryinBoston.
Serum levels of hsCRP were determined
by a latex-enhanced immunonephelo-
metric assay on a BN II analyzer (Dade
Behring, Newark, DE). The day-to-day
variability of each biomarker assay was
10%. A1C levels were determined from
whole blood at the time of collection us-
ing high-performance liquid chromatog-
raphy in the DCCT Central A1C
Laboratory.
Creatinine clearance and urinary al-
buminexcretionrate(AER)wereassessed
annually in the DCCT, using 4-h timed
urine collections. Serum albumin and se-
rum creatinine were also measured annu-
ally. As in prior analyses from the DCCT,
we deﬁned incident sustained microalbu-
minuria as the ﬁrst development of uri-
nary AER of 28 g/min (40 mg/24 h)
among those without microalbuminuria
atbaselinethatwassustainedforatleast1
year.
Statistical analysis
We initially examined the relationships
between tertiles of inﬂammatory biomar-
kers and baseline characteristics of the
study population. Spearman correlation
coefﬁcients were used to test for associa-
tions between continuous variables. We
then performed mixed-effects regression
modelingusingtimeasacontinuousvari-
able and assumed randomly varying in-
tercepts and slopes for each participant to
determinetheaveragechangeinAERover
time. We tested for differences across ter-
tiles of the inﬂammatory biomarkers by
modeling time  biomarker tertile inter-
action terms to examine whether the
slope of change of AER (dependent vari-
able) was signiﬁcantly different between
tertiles of biomarkers (independent vari-
able). Therefore, the magnitude of associ-
ation between tertiles of biomarkers and
AER is represented as a difference in
change in AER per year in tertiles 2 and 3
compared with the lowest tertile (referent
group) when averaged over the 9-year
study period.
In addition, we used proportional
hazards regression to estimate the rate ra-
tios and 95% CI for the relationships of
each inﬂammatory biomarker with the
development of sustained microalbumin-
uria. We considered several possible con-
founders including age, sex, duration of
diabetes, A1C, treatment assignment,
baseline AER, smoking status (never,
past, or current), baseline systolic blood
pressure (SBP), diastolic blood pressure
(DBP), pulse pressure (difference be-
tweenSBPandDBPatbaseline),andBMI.
SAS (version 8.2, SAS Institute, Cary NC)
was used for all analyses.
This study was approved by the Part-
ners’ Healthcare Brigham and Women’s
Hospital Human Research Committee In-
stitutional Review Board.
RESULTS— The DCCT comprised a
young cohort (median age 27 years) with
almost equal numbers of predominantly
whitemaleandfemaleparticipants(Table
1). The median duration of type 1 diabe-
tes was 51 months. The majority of this
population was normotensive at enroll-
ment (only 24 had SBP 140 mmHg and
26 had DBP 90 mmHg at baseline) and
had normal plasma creatinine and di-
rectlymeasuredcreatinineclearance.Less
than 7% of the study population had
missing data for one or more biomarkers;
medianandrangevalueswithintertilesof
each biomarker are given in Table 1. In
looking at the distribution of the data, we
notedthatonly5%oftheparticipantshad
baseline hsCRP 7.8 mg/l.
At baseline, cross-sectional measures
of sICAM-1 and sVCAM-1 were associ-
ated with (r  0.34, P  0.001) and
sTNFR-1 was also signiﬁcantly correlated
with sICAM-1 (r  0.32, P  0.001) and
sVCAM-1 (r  0.31, P  0.001). hsCRP
was associated with sTNFR-1 (r  0.12,
P  0.001), and sICAM (r  0.17, P 
0.001) but not sVCAM-1 (r  0.04, P 
0.17). By Spearman correlation, A1C was
signiﬁcantly associated with hsCRP (r 
0.11,P0.001)andsICAM-1(r0.18,
P  0.001), and diabetes duration were
signiﬁcantly associated with hsCRP (r 
0.10, P  0.001), sTNFR-1 (r  0.13,
P  0.001), and sICAM-1 (r  0.05, P 
0.04) at baseline. We additionally ob-
served a statistically signiﬁcant direct
cross-sectional correlation between base-
lineAERandsICAMtertiles(medianAER
7.0 vs. 7.5 vs. 8.0 g/min, P  0.01) but
not between AER and other biomarkers.
Evaluation of the mean change in
AER over time by hsCRP tertiles demon-
stratednodifferenceinAERexcretionun-
til after year 7, and no consistent direct
relationship was seen between higher
hsCRP and change in AER (Fig. 1A). In
examining the mean change in AER over
time stratiﬁed by tertiles of baseline
sTNFR-1, sICAM-1, and sVCAM-1 (Figs.
1B–D),wenotedasteeperincreaseinAER
over time for those in the highest tertile
of each of these markers; however, this
difference did not become notable until
year 7 of follow-up for sTNFR-1 and
sVCAM-1. In contrast, those in the highest
tertile of sICAM-1 experienced a steeper in-
crease in AER beginning after year 3 that
persisted throughout follow-up.
Unadjusted mixed-effects regression
showed that subjects in the highest tertile
of baseline sICAM-1 had a signiﬁcant 8.1
g/min greater increase in AER per year
comparedwiththatofsubjectsinthelow-
est tertile of baseline sICAM-1 (P 
0.002). In contrast, there were no signif-
icant effects of hsCRP (P  0.54),
sTNFR-1 (P  0.45), or sVCAM-1 (P 
0.15) on change in AER over time (sup-
plementalTableA2,availableinanonline
appendix at http://dx.doi.org/10.2337/
dc08-0277). In multivariable models ad-
justed for age, sex, duration of diabetes,
baseline A1C, and treatment assignment,
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g/min increase in AER per year (P 
0.04) among those in the highest versus
lowest tertiles of baseline sICAM-1 (sup-
plementalTableA3,availableinanonline
appendix at http://dx.doi.org/10.2337/
dc08-0277). We did not observe signiﬁ-
cant associations between smoking
(0.93 g   min
1   year
1, P  0.67) or
BMI (0.25 g   min
1   year
1 per 1
unit increase in BMI, P  0.49) and
changeinAERovertime.Whenthesetwo
variables were included in the fully ad-
justed mixed-effects model, they did not
meaningfully alter the association be-
tween the highest tertile of sICAM-1 and
change in AER (6.2 g   min
1   year
1
increase, P  0.02); neither of these co-
variates have a signiﬁcant associations
with change in AER, so they were not in-
cluded in the ﬁnal model.
In addition to the signiﬁcant effect of
sICAM-1,wealsoobservedthattheinten-
sive treatment group experienced a lower
rate of increase in AER excretion by 5.3
g   min
1   year
1 (P  0.01) compared
with the conventional treatment group.
Each additional year of diabetes duration
was independently associated with a sig-
niﬁcant 0.09 g   min
1   year
1 increase
in AER (P  0.001), and each percent
increase in A1C at baseline was directly
associated with a 2.6 g   min
1   year
1
increase in AER (P  0.01). The covari-
ates of baseline SBP, DBP, pulse pressure,
and BMI were not signiﬁcantly associated
with change in AER over time in univari-
ate analyses and did not inﬂuence the re-
sults when included in the fully adjusted
models. Inclusion of baseline AER in the
multivariable mixed-effects regression
model did not meaningfully alter the as-
sociations between the highest tertile of
sICAM (5.4 g   min
1   year
1 increase
in AER, P  0.04) or the other covariates.
There were 725 participants in the pri-
mary prevention group and 642 in the
secondary prevention group. In the fully
adjusted mixed-effects regression mod-
els, the rate of AER increase was 1.44 g  
min
1   year
1 in the primary prevention
groupand8.71g min
1 year
1inthe
secondarypreventiongroup.Atestforthe
interaction term of the highest tertile of
ICAM-1 and prevention group yielded a
signiﬁcant P value of 0.005.
Further analysis of the 1,367 partici-
pants without microalbuminuria at base-
line (AER 40 mg/24 h) showed that 97
developed new sustained microalbumin-
uria. Using proportional hazards regres-
sion, we observed a signiﬁcantly higher
incidence of sustained microalbuminuria
amongthosewithhigherbaselinelevelsof
sICAM-1 (Ptrend  0.03). The rate ratio
for sustained microalbuminuria contrast-
ing the top versus bottom tertile of sI-
CAM-1 levels was 1.67 (95% CI 0.96–
2.92). We did not observe signiﬁcant
associations between other biomarkers
and sustained new incident microalbu-
minuria (supplemental online Table A4,
available in an online appendix). Again,
the covariates of baseline SBP, DBP, pulse
pressure, and BMI were not signiﬁcantly
associated with incident microalbumin-
uria in univariate Cox proportional haz-
ards analyses, and results were
unchanged when each of these covariates
wasincludedinthefullyadjustedmodels.
CONCLUSIONS — We examined
four candidate inﬂammatory biomarkers
in individuals with type 1 diabetes and
found that only sICAM-1 levels were sig-
niﬁcantly associated with increasing AER
over time as well as the development of
new microalbuminuria. Furthermore, the
association between baseline sICAM-1
andincreasingAERovertimeappearedto
be more pronounced in those in the sec-
ondary prevention group who already
hadevidenceofvascularinvolvement(di-
abetic retinopathy). This may reﬂect the
important role of sICAM-1 as a mediator
of progressive microvascular disease,
which often manifests as nephropathy in
conjunction with retinopathy in diabetes.
Other baseline covariates that inde-
pendently inﬂuenced progressive albu-
minuriainthisstudypopulationincluded
longer duration of diabetes and higher
baseline A1C. As expected and consistent
with previously reported ﬁndings for the
development of sustained microalbumin-
uriaintheDCCTstudy,assignmenttothe
intensiveglucosecontroltreatmentgroup
was protective against progressive albu-
minuria or incident microalbuminuria.
Increases in AER began to appear af-
ter 3 years of follow-up among those with
values in the highest tertile of sICAM-1
levels. In contrast, there was a gradual in-
crease in AER over time that was statisti-
cally independent of the levels of hsCRP,
Table 1—Baseline characteristics of participants in DCCT trial
All participants
Age (years) 27 (22–32)
Sex (% men/% women) 761 (53)/680 (47)
White 1,391 (96.5)
BMI (kg/m
2) 23.3 (21.3–25.2)
Ever smoked 516 (36)
Duration of diabetes (months) 51 (21–109)
SBP (mmHg) 114 (106–122)
DBP (mmHg) 72 (68–80)
A1C (%) 8.7 (7.8–9.9)
Plasma creatinine (mg/dl) 0.8 (0.7–0.9)
Creatinine clearance (ml/min) 126 (110–143)
Baseline AER (g/min) 8.0 (5–13)
hsCRP (mg/l)
Tertile 1 (n  450) 0.28 (0.4–0.54)
Tertile 2 (n  451) 0.88 (0.55–1.42)
Tertile 3 (n  449) 3.09 (1.43–45.2)
sTNFR-1 (pg/ml)
Tertile 1 (n  463) 833 (512–925.7)
Tertile 2 (n  464) 1011 (926.1–1122.1)
Tertile 3 (n  463) 1261 (1122.5–2910.8)
sICAM-1 (ng/ml)
Tertile 1 (n  465) 235 (52.2–258.1)
Tertile 2 (n  466) 282 (258.2–306.2)
Tertile 3 (n  465) 346 (306.3–847.1)
sVCAM (ng/ml)
Tertile 1 (n  465) 366 (125–408.8)
Tertile 2 (n  465 448 (409.0–492.7)
Tertile 3 (n  465) 558 (492.9–1180.7)
Data are median (interquartile range) or number (%). n  1,441.
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increases in AER are small in magnitude,
their clinical importance is supported by
data showing that AER in what has been
considered the “normal range” (30
mg/24 h) confers independent and signif-
icantriskforcardiovasculareventsand/or
death in multiple studies including pop-
ulation-based (8) and cardiac disease (9)
cohorts. Especially relevant to our ﬁnd-
ings that sICAM predicts incident mi-
croalbuminuria is the report that
microalbuminuria was strongly predic-
tive of subsequent CVD events in the
Pittsburgh Epidemiology of Diabetes
Complications longitudinal follow-up
study of type 1 diabetic subjects (10).
Hyperglycemia impairs vascular en-
dothelial cell function, probably in part
through oxidation of LDL and increased
formation of free radicals. For example,
generation of reactive oxygen species by
polymorphonuclear leukocytes and
mononuclear cells has been noted to in-
crease by 200% between baseline and
2 h in a study of 14 healthy humans given
a 75-g glucose load (11). Free radicals, in
turn, stimulate the release of proinﬂam-
matory cytokines, which induce the
expression of adhesion molecules, in-
cluding ICAM-1 and VCAM-1 (12). This
association may be mediated through hy-
perglycemia-induced increased nuclear
factor-B binding, as transcription for
ICAM-1 is regulated by nuclear factor-B
(13).
Amemberoftheimmunoglobulinsu-
perfamily, ICAM-1 is upregulated in acti-
vated endothelial cells and is central in
migration of inﬂammatory cells into tis-
sues. Poor glycemic control is associated
with increased expression of ICAM-1 and
other markers of endothelial activation in
type 1 diabetes (14). Furthermore, insu-
lin administration has been reported to
directly decrease ICAM-1 in in vitro stud-
ies of human cultured endothelial aortic
cells (15) as well as in an in vivo study of
human subjects in which plasma glucose
was maintained at baseline levels (16).
These data are consistent with our obser-
vation that those in the intensive control
group of the DCCT experienced signiﬁ-
cantdecreasesinICAM-1andVCAM-1at
3 years of follow-up (17). In considering
why baseline ICAM-1 was the most con-
sistent and signiﬁcant predictor of subse-
quent nephropathy progression in our
analyses, we hypothesize that ICAM-1
may be a key molecule in the common
ﬁnal pathway of endothelial cell activa-
tion, inﬂammation, and injury in the kid-
ney that manifests clinically as elevated
AER in the early stages of nephropathy.
For example, CRP is thought to enhance
expression of endothelial adhesion mole-
cules ICAM-1 and VCAM-1 in local tis-
sues, whereas TNF- is thought to prime
neutrophil inﬁltration into target organs
(18). Therefore, elevated CRP and TNF-
levels may reﬂect a generalized and non-
speciﬁc inﬂammatory condition in con-
trast with a more restricted state of active
vascular endothelial dysfunction associ-
ated with adhesion molecules ICAM-1
and VCAM-1.
As for why sICAM-1 but not sVCAM-1
was strongly associated with increasing
AER,ICAM-1appearstobeconstitutively
expressed by endothelial cells (19),
whereas acute upregulation of VCAM-1
may be central in initiation of atheroscle-
rosis (20). Thus, elevated plasma levels of
ICAM-1 may be indicative of sustained
inﬂammatory endothelial activity and in-
juryinthekidneythatmanifestsclinically
Figure 1—A: Mean change over time of AER stratiﬁed by tertile (T) of baseline hsCRP. B: Mean change over time of AER stratiﬁed by tertile of
baseline sTNFR-1. C: Mean change over time of AER stratiﬁed by tertile of baseline sICAM-1. D: Mean change in AER over time stratiﬁed by tertile
ofbaselinesVCAM-1.VerticalbarsrepresentSEM.Notethatsamplesizesforeachbiomarkervaryslightlyateachtimepointbecauseofmissingdata
of individual baseline markers.
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time.
ICAM-1 and VCAM-1 have been di-
rectly associated with increased AER in
individuals with type 1 diabetes in cross-
sectional studies (7), but this is the ﬁrst
investigation to our knowledge to report
thatsICAM-1isanindependentpredictor
of subsequent increased urinary albumin
excretion or development of new mi-
croalbuminuria. Interestingly, animal
models of diabetic nephropathy have re-
vealed that ICAM-1 knockout mice have
signiﬁcantly lower levels of AER in strep-
tozocin-induced (type 1) diabetes (21).
Renal tissue in both these animal models
alsodemonstratedsigniﬁcantlydecreased
numbers of interstitial inﬂammatory cells
in ICAM-1-deﬁcient animals as well as a
reduction in histologic kidney damage.
These data from humans and animals
support the concept that endothelial dys-
function plays an important role in pro-
moting progressive renal disease in
diabetes.Moreover,ICAM-1isimplicated
in progression of vascular atherosclerotic
disease (22). For these reasons, we hy-
pothesize that ICAM-1 may represent an
important pathogenic link between vas-
cular endothelial dysfunction and kidney
dysfunction and its associated cardiovas-
cular risk in individuals with diabetes.
The Steno hypothesis proposed that
albuminuria reﬂects a systemic vascular
endothelial dysfunction that promotes
atherosclerotic processes in type 1 diabe-
tes, and increased albuminuria has been
associated with cardiovascular and all-
cause mortality in large prospective clini-
cal investigations (8,9). In conjunction
with previous reports that sICAM-1 is an
independent predictor of coronary ath-
erosclerotic disease progression but not
acute myocardial infarction (23) and of
progressive peripheral artery disease but
not acute vascular occlusion (24), our
ﬁndings that sICAM-1 is a strong predic-
tor of increasing albuminuria over time
support the theory that elevated AER is a
harbinger of progressive atherosclerosis.
Moreover, sICAM-1 may play a central
role in the association between albumin-
uria and CVD.
Limitations of the current study in-
clude the small number of nonwhite par-
ticipants, typical for type 1 diabetes, that
may limit the generalizability of these ob-
served associations to minority, older, or
type 2 diabetic populations. The possibil-
ity of residual confounding in these mul-
tivariable models is also present, as in any
observationalepidemiologicalstudy.Fur-
thermore, these data were collected be-
fore the time of widespread ACE
medication use, now an established strat-
egy in slowing progressive nephropathy
in type 1 and type 2 diabetes, so the in-
ﬂuence of therapy upon these biomarkers
andalbuminuriacannotbeexamined.In-
terestingly, angiotensin II promotes up-
regulation of ICAM-1 and VCAM-1 on
endothelial cells (25), and reduction of
angiotensin II levels by ACE inhibition
may have a multifactorial effect in de-
creasingalbuminuriaincludingreduction
of adhesion molecules in addition to di-
minishing glomerular ﬁltration pressure
and promoting proﬁbrotic pathways.
There is a further possibility that the re-
sults are inﬂuenced by differences in pro-
portions of missing data over time. We
examined the numbers of participants
with missing data in each stratum of bi-
omarker (with a special focus on years 6
to 9, for which there is higher attrition in
AER data), however, and found that the
missing AER data were equally distrib-
uted among all strata of each biomarker.
These limitations are balanced by
somenotablestrengthsofthisprospective
investigationincludingtherelativelylarge
and well-deﬁned study cohort with re-
peated laboratory measures for up to 9
yearsoffollow-up.Thedirectlymeasured
AER with repeated timed urine collec-
tionsisalsoastrengththatallowedusto
examine change in AER over time and
examine its relation to novel inﬂamma-
tory biomarkers.
In summary, we report that higher
baselineplasmaICAM-1isindependently
associated with increasing AER over time
as well as with incident sustained mi-
croalbuminuria in type 1 diabetes. These
ﬁndings suggest that inﬂammation and
endothelial dysfunction play important
rolesinprogressivenephropathyintype1
diabetes and that sICAM-1 may be a po-
tential early biomarker that would allow
for risk stratiﬁcation of patients.
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